Google
Trusted Resources: News & Events
Latest announcements and gatherings
Arginine Therapy Shows Positive Impacts on Sickle Cell Disease in ASH 2022 Data
Individuals with sickle cell disease (SCD) present at the emergency department (ED) and are often admitted for hospitalization most commonly for vaso-occlusive pain episodes (VOEs). These episodes also referred to as “pain crises” due to the intense pain experienced by patients, cause an acute arginine (Arg) deficiency.
Arg supplementation has shown positive impacts on blood pressure, and cardiopulmonary function, and has decreased the length of patient’s hospital stay. With supplementation, patients often require lower doses of opioids to manage the episode.
Previous research demonstrated intravenous (IV) Arg improves mitochondrial (Mito) function. Beyond this, not much is understood about the precise mechanisms that enable Arg to mediate such benefits in this patient population.
+myBinderRelated Content
-
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)AmerisourceBergen, a global healthcare s...
-
Stress and the Home Environment in Caregivers of Children With Sickle CellObjective: Caregivers of young children...
-
Lamia Barakat, PhDLamia P. Barakat, PhD, is the Director o...
-
Novel use of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemiaHydroxyurea treatment is recommended for...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
CMO Speaks: Making ED Care Better for SCD – Progress in 2023Welcome to CMO Speaks, a blog featuring ...
-
Vanderbilt University Medical CenterThe Vanderbilt-Meharry-Matthew Walker Ce...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.